EMA Authorised: Xermelo (telotristat etiprate) — SERB SAS

View source ↗

Summary

EMA authorised Xermelo (telotristat etiprate) for the treatment of carcinoid syndrome–related diarrhea in adults with neuroendocrine tumors, with orphan designa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoid Syndrome
• Neuroendocrine Tumor

Drugs mentioned

• XERMELO (telotristat ethyl)

Snippet

Status: Authorised. Therapeutic area: Carcinoid Tumor;Neuroendocrine Tumors. MAH: SERB SAS. Decision date: 05/12/2025. Orphan medicine